Sunkyu Kim

Vice President, Drug discovery-Pharmacology

Sunkyu Kim is a highly accomplished pharmaceutical executive currently serving as Vice President at Incyte, a position he has held since September 2018.2 With a strong background in drug discovery and development, Kim has made significant contributions to the field of oncology throughout his career.

Career Highlights

Current Role at Incyte: As Vice President at Incyte, Kim is responsible for:

Leading preclinical drug discovery programs
Overseeing in-vitro/in-vivo pharmacology and target discovery groups for targeted therapy and immuno-oncology
Reviewing and supporting external opportunities from academic and industry partners
Participating in discovery and development leadership teams2

Previous Positions: Before joining Incyte, Kim held several notable positions:

Senior Director at FORMA Therapeutics (2016-2018)
Director of Translational Medicine Leader at Roche (2015-2016)
Group Leader in Oncology Drug Discovery at Novartis Institutes for Biomedical Research (2011-2015)
Various roles at Novartis, including Senior Research Investigator (2001-2011)1

Key Achievements

CDK4/6 Program: Kim played a pivotal role in launching the CDK4/6 program at Novartis, which resulted in FDA-approved drugs.
SERD Program: He led the development of the SERD program, which is currently in clinical trials and has the potential to impact breast cancer therapy.
Ribociclib (Kisqali): As the main discovery scientist for Ribociclib, Kim was instrumental in developing the clinical strategy, including indication selection, combination strategies, and biomarker plans.2